Introduction Immune checkpoint inhibitors, targeting cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) and the programmed cell death protein-1 (PD-1)/programmed cell death …

Mycosis fungoides (MF) and Sézary syndrome (SS) comprise approximately 53% of
cutaneous lymphomas. Both MF and SS may clinically and histologically mimic benign skin …

Genetic humanization, which involves replacing mouse genes with their human
counterparts, can create powerful animal models for the study of human genes and …

Chimeric antigen receptor T-cell (CAR-T) therapy has been prosperous in the treatment of
patients with various types of relapsed/refractory (R/R) B-cell malignancies including diffuse …

Marine secondary metabolites are a promising source of unexploited drugs that have a wide
structural diversity and have shown a variety of biological activities. These compounds are …

Disease overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell
lymphoproliferative disorders involving the skin, the majority of which may be classified as …

We have used homologous recombination in ES cells to engineer B cell-deficient mice that
are incapable of expressing endogenous immunoglobulin heavy and kappa light chain …

Both mycosis fungoides (MF) and Sézary syndrome (SS) have a chronic, relapsing course,
with patients frequently undergoing multiple, consecutive therapies. Treatment is aimed at …

Abstract Disease Overview Cutaneous T‐cell lymphomas (CTCL) are a heterogenous group
of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis …

Cutaneous T cell lymphoma (CTCL) is a cancer of skin-homing T cells with variants that
include leukemic CTCL (L-CTCL), a malignancy of central memory T cells (TCM), and …